Literature DB >> 26558383

MicroRNA in ovarian function.

S W Maalouf1, W S Liu1, J L Pate2.   

Abstract

The mammalian ovary is a dynamic organ. The coordination of follicle recruitment, selection, and ovulation and the timely development and regression of the corpus luteum are essential for a functional ovary and fertility. Deregulation of any of these processes results in ovarian dysfunction and potential infertility. MicroRNA (miRNA) are short noncoding RNA that regulate developmental processes and time-sensitive functions. The expression of miRNA in the ovary varies with cell type, function, and stage of the estrous cycle. miRNA are involved in the formation of primordial follicles, follicular recruitment and selection, follicular atresia, oocyte-cumulus cell interaction, granulosal cell function, and luteinization. miRNA are differentially expressed in luteal cells at the various stages of the estrous cycle and during maternal recognition of pregnancy, suggesting a role in luteal development, maintenance, and regression. An understanding of the patterns of expression and functions of miRNA in the ovary will lead to novel therapeutics to treat ovarian dysfunction and improve fertility and, potentially, to the development of better contraceptives.

Entities:  

Keywords:  Corpus luteum; Follicle; MicroRNA; Ovary; Reproduction

Mesh:

Substances:

Year:  2015        PMID: 26558383     DOI: 10.1007/s00441-015-2307-4

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  33 in total

1.  CircRNAs in Xiang pig ovaries among diestrus and estrus stages.

Authors:  Xi Niu; Yali Huang; Huan Lu; Sheng Li; Shihui Huang; Xueqin Ran; Jiafu Wang
Journal:  Porcine Health Manag       Date:  2022-06-23

Review 2.  The role of miRNAs in regulating adrenal and gonadal steroidogenesis.

Authors:  Salman Azhar; Dachuan Dong; Wen-Jun Shen; Zhigang Hu; Fredric B Kraemer
Journal:  J Mol Endocrinol       Date:  2020-01       Impact factor: 5.098

3.  Paracrine effects of human amniotic epithelial cells protect against chemotherapy-induced ovarian damage.

Authors:  Qiuwan Zhang; Shixia Bu; Junyan Sun; Minhua Xu; Xiaofen Yao; Kunyan He; Dongmei Lai
Journal:  Stem Cell Res Ther       Date:  2017-11-28       Impact factor: 6.832

4.  Chi-miR-4110 promotes granulosa cell apoptosis by targeting Sma- and Mad-related protein 2 (Smad2) in the caprine ovary.

Authors:  Xiaopeng An; Yuxuan Song; Jinxing Hou; Yue Zhang; Kaiwen Chen; Haidong Ma; Xinyan Zhao; Guang Li; Kexin Gao; Shan Wang; Binyun Cao; Yueyu Bai
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

5.  The Adequate Corpus Luteum: miR-96 Promotes Luteal Cell Survival and Progesterone Production.

Authors:  Bushra T Mohammed; Sadanand D Sontakke; Jason Ioannidis; W Colin Duncan; F Xavier Donadeu
Journal:  J Clin Endocrinol Metab       Date:  2017-07-01       Impact factor: 5.958

Review 6.  Role of microRNAs in premature ovarian insufficiency.

Authors:  Ying Guo; Junyan Sun; Dongmei Lai
Journal:  Reprod Biol Endocrinol       Date:  2017-05-12       Impact factor: 5.211

7.  MicroRNA Mediating Networks in Granulosa Cells Associated with Ovarian Follicular Development.

Authors:  Baoyun Zhang; Long Chen; Guangde Feng; Wei Xiang; Ke Zhang; Mingxing Chu; Pingqing Wang
Journal:  Biomed Res Int       Date:  2017-02-19       Impact factor: 3.411

8.  A miRNA target network putatively involved in follicular atresia.

Authors:  F X Donadeu; B T Mohammed; J Ioannidis
Journal:  Domest Anim Endocrinol       Date:  2016-08-13       Impact factor: 2.290

9.  miRNA‑504 inhibits p53‑dependent vascular smooth muscle cell apoptosis and may prevent aneurysm formation.

Authors:  Xue Cao; Zhenguo Cai; Junyan Liu; Yanru Zhao; Xin Wang; Xueqi Li; Hongyuan Xia
Journal:  Mol Med Rep       Date:  2017-06-28       Impact factor: 2.952

10.  MiR-124 inhibits invasion and induces apoptosis of ovarian cancer cells by targeting programmed cell death 6.

Authors:  Li Yuan; Shaolin Li; Qi Zhou; Dong Wang; Dongling Zou; Jin Shu; Yu Huang
Journal:  Oncol Lett       Date:  2017-10-10       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.